AlexanderMontoMD

PubMed

• Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success.
  Méndez-Lagares, G.,Lu, D.,Chen, C.,Terrault, N.,Segal, M. R.,Khalili, M.,Monto, A.,Shen, H.,Manos, M. M.,Lanier, L. L.,Ryan, J. C.,McCune, J. M.,Hartigan-O'Connor, D. J.> ;J. Immunol.. 2017 Dec 22
• Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresp...
  Myrna L. Cozen, James C. Ryan, Hui Shen, Ramsey Cheung, David E. Kaplan, Christine Pocha, Norbert Bräu, Ayse Aytaman, Warren N. Schmidt, Marcos C. Pedrosa, Bhupinderji...> ;Digestive Diseases and Sciences. 2016 Apr 8
• Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer?
  Fraenkel, L.,Lim, J.,Garcia-Tsao, G.,Reyna, V.,Monto, A.> ;J. Clin. Gastroenterol.. 2015 Jul 15
• Variation in Treatment Priorities for Chronic Hepatitis C: A Latent Class Analysis.
  Fraenkel, L.,Lim, J.,Garcia-Tsao, G.,Reyna, V.,Monto, A.,Bridges, J. F.> ;Patient. 2015 Nov 01
• Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals - authors' reply.
  Saxena, V.,Monto, A.,Terrault, N.> ;Aliment. Pharmacol. Ther.. 2014 May 23
• Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
  Saxena, V.,Manos, M. M.,Yee, H. S.,Catalli, L.,Wayne, E.,Murphy, R. C.,Shvachko, V. A.,Pauly, M. P.,Chua, J.,Monto, A.,Terrault, N. A.> ;Aliment. Pharmacol. Ther.. 2014 Mar 25
• Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma.
  Ho, E. Y.,Cozen, M. L.,Shen, H.,Lerrigo, R.,Trimble, E.,Ryan, J. C.,Corvera, C. U.,Monto, A.> ;HPB (Oxford). 2014 Jan 29
• Contrast-Enhanced CT Quantification of the Hepatic Fractional Extracellular Space: Correlation With Diffuse Liver Disease Severity.
  Zissen, M. H.,Wang, Z. J.,Yee, J.,Aslam, R.,Monto, A.,Yeh, B. M.> ;AJR Am J Roentgenol. 2013 Nov 23
• Impaired lymphocyte reactivity measured by immune function testing in untransplanted patients with cirrhosis.
  Yee RM Lehil MS Rongey C Shen H Cozen ML Monto A Ryan JC > ;Clin Vaccine Immunol . 2013 Apr
• Monocyte Activation in HIV/HCV Coinfection Correlates with Cognitive Impairment.
  Rempel H Sun B Calosing C Abadjian L Monto A Pulliam L > ;PLoS One . 2013
• Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection.
  Sun B Abadjian L Rempel H Monto A Pulliam L > ;J Acquir Immune Defic Syndr . 2013 Feb 1
• Is IL28B genotype associated with more than one aspect of viral clearance?
  Monto A Ryan J > ;Hepatology . 2012 Dec
• Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and ...
  Yee HS Chang MF Pocha C Lim J Ross D Morgan TR Monto A > ;Am J Gastroenterol . 2012 May
• Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo
  Satish K. Pillai, Mohamed Abdel-Mohsen, John C. Guatelli, Mark Skasko, Alexander Monto, Katsuya Fujimoto, Steven A. Yukl, Warner C. Greene, Helen Kovari, Andri Rauch, ...> ;Proceedings of the National Academy of Sciences of the United States of America. 2012 Feb 21
• Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C.
  Vermehren J Yu ML Monto A Yao JD Anderson C Bertuzis R Schneider G Sarrazin C > ;J Clin Virol . 2011 Oct
• Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant.
  Bacchetti P Boylan RD Terrault NA Monto A Berenguer M > ;Int J Biostat . 2010
• Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice ...
  Yee HS Currie SL Tortorice K Cozen M Shen H Chapman S Cunningham F Monto A > ;Dig Dis Sci . 2011 Aug
• Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis.
  Bacchetti P Boylan R Astemborski J Shen H Mehta SH Thomas DL Terrault NA Monto A > ;PLoS One . 2011
• Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid.
  Lee SR Kardos KW Schiff E Berne CA Mounzer K Banks AT Tatum HA Friel TJ Demicco MP Lee WM Eder SE Monto A Yearwood GD Guillon GB Kurtz LA Fischl M Unangst JL Kriebel L...> ;J Virol Methods . 2011 Mar
• The human fetal immune response to hepatitis C virus exposure in utero.
  Babik JM Cohan D Monto A Hartigan-O'Connor DJ McCune JM > ;J Infect Dis . 2011 Jan 15
• Periprocedural complications by Child-Pugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular c...
  Russell JS Sawhney R Monto A Nanavati S Davoren JB Aslam R Corvera CU > ;Am J Surg . 2010 Nov
• 15 citations
  Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop
  Alexander Monto, Robert T. Schooley, Jennifer C. Lai, Mark S. Sulkowski, Raymond T. Chung, Jean-Michel Pawlotsky, John G. McHutchison, Ira M. Jacobson> ;The American Journal of Gastroenterology. 2010 May 1
• Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C.
  Chapko MK Yee HS Monto A Dominitz JA > ;Vaccine . 2010 Feb 17
• Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Progra...
  Garcia-Tsao G Lim JK > ;Am J Gastroenterol . 2009 Jul
• Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study.
  Tsui JI Whooley MA Monto A Seal K Tien PC Shlipak M > ;J Card Fail . 2009 Jun
• Join now to see all

Abstracts/Posters

• Role of retroviral restriction factors in the interferon-anpha-mediated suppression of HIV-1 in vivo.
  Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Rauch A, Cavassini M, Battegay M, Hirschel B, Vernazza P, Bernasconi E, Ledergerb, Proceedings of the National Academy of Sciences

Lectures

• Evaluation and Management of Hepatitis C Patients with Advanced Liver Disease. 
  Geriatric Research, Education, and Clinical Center (GRECC) at the Minneapolis Veterans Affairs
• Hepatitis C and Diabetes Mellitus. 
  VHA-DoD Diabetes Specialty Practice Group Educators Conference, Salt Lake City, UT
• Natural History of Hepatitis C Virus: Clinical Consequences and Fibrosis Progression. 
  Department of Veterans Affairs, San Francisco HCRC Pharmacy Preceptorship, San Francisco, CA
• Liver Disease in Patients with HIV. 
  U.C.S.F. Gastroenterology Division Grand Rounds, San Francisco, CA
• Medical Management of End Stage Liver Disease. 
  Department of Veterans Affairs Second Liver Transplant Coordinators Preceptorship, Portland, OR
• Management of Recurrent Hepatitis C Post-Transplant. 
  Department of Veterans Affairs Second Liver Transplant Coordinators Preceptorship, Portland, OR
• Liver Masses. 
  30th Annual U.C.S.F. “Advances in Internal Medicine” Course, San Francisco, CA
• The Ethics of Liver Transplantation. 
  San Francisco Veterans Affairs Medical Center Annual Ethics Lecture Series, San Francisco, CA
• Hepatitis C Virus Infection. 
  24th Annual U.C.S.F. “Advances in Infectious Diseases” Course, San Francisco, CA
• Gastroenterology Division Fellows’ Course. 
  San Francisco, CA
• Hepatitis B and Hepatitis C Issues Before and After Orthotopic Liver Transplantation. 
  Department of Veterans Affairs National Liver Transplantation Symposium, Nashville, TN
• Benign and Malignant Liver Tumors. 
  U.C.S.F. Gastroenterology Division Fellows’ Course, San Francisco, CA
• Steatosis in Chronic Hepatitis C. 
  UCSF-Stanford Annual Gastroenterology Research Symposium, Stanford, CA
• Liver Telehealth Resource Guide. 
  Department of Veterans Affairs, Veterans Health Administration
• Hepatitis C Treatment Update. 
  Northern California Society of Gastroenterology Nurses Annual Conference, Folsom, CA
• Evaluation and Management of Chronic Hepatitis C. 
  Geriatric Research, Education, and Clinical Center (GRECC) at the Minneapolis Veterans Affairs
• Diagnosis and Management of Acute Hepatitis C. U.C.S.F. 
  24th Annual “The Medical Management of HIV/AIDS,” San Francisco, CA
• Medical Management of End Stage Liver Disease. 
  Department of Veterans Affairs Liver Transplant Coordinators Preceptorship, Portland, OR
• Benefits of Hepatitis C Virus Treatment. 
  American Liver Foundation and California Pacific Medical Center, San Francisco, CA
• Emerging Treatments for Liver Disease and GERD. 
  American Liver Foundation and California Pacific Medical Center, San Francisco, CA
• The Great Debate: When to treat hepatitis C in our HIV coinfected patients. 
  U.C.S.F. 24th Annual “The Medical Management of HIV/AIDS,” San Francisco, CA
• Co-morbid conditions associated with hepatitis C. 
  Chicago, IL
• Medical Management of Cirrhosis. 
  U.C.S.F. Gastroenterology Division Grand Rounds, San Francisco, CA
• Treatment of hepatitis C in active injection drug users: Cons. 
  American Association for the Study of Liver Diseases (AASLD) Single Topic Conference
• Acute Pancreatitis. 
  U.C.S.F. Gastroenterology Division Fellows’ Course, San Francisco, CA
• Join now to see all

Other

• Monocyte activation in HIV/HCV coinfection correlates with cognitive impairment. 
  Rempel H, Sun B, Calosing C, Abadjian L, Monto A, Pulliam L, PLoS ONE
• Impaired lymphocyte reactivity as measured by immune function testing in untransplanted patients with cirrhosis. 
  Yee RM, Lehil MS, Rongey C, Shen H, Cozen ML, Shen H, Monto A, Ryan JC, Clinical and Vaccine Immunology
• Nonresponse to interferon- anpha based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. 
  Cozen ML, Ryan JC, Shen H, Lerrigo R, Yee RM, Sheen E, Wu R, Monto A, PLoS ONE
• Is IL28B genotype associated with more than one aspect of viral clearance? 
  Monto A, Ryan JC, Hepatology
• Managing hepatitis C infection in the VA health care system: a roundtable discussion. 
  Ross D, Beste L, Dieperink E, Downey K, Monto A, Smith, J, Federal Practitioner Supplement
• Retreatment with consensus interferon/ribavirin for hepatitis C following nonresponse or relapse to pegylated interferon and ribavirin: results from a national VA clin... 
  Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, Cunningham F, Monto A, Digestive Diseases and Sciences
• Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: Non-Markov multistate model analysis. 
  Bacchetti P, Boylan RD, Astemborski J, Shen H, Mehta S, Thomas D, Terrault N, Monto A, PLoS ONE
• Cost-effectiveness of hepatitis A vaccination for individuals with chronic hepatitis C. 
  Chapko MK, Yee HS, Monto A, Dominitz JA, Vaccine
• Multidisciplinary perspectives on management of hepatocellular carcinoma: a roundtable discussion. 
  Monto A, Kohlwes J, Raval GG, Mehta P, El-Serag HB, Taddei T, Federal Practitioner
• A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. 
  Currie SL, Ryan JC, Tracy D, Wright TL, George S, McQuaid R, Kim M, Shen H, Monto A, Drug and Alcohol Dependence
• Implementation of a multidisciplinary team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. 
  Chang TT, Sawhney R, Monto A, Davoren JB, Kirkland JG, Stewart L, Corvera CU, HPB
• The association of human immunodeficiency virus infection with spontaneous hepatitis C virus resolution and level of viremia among injection drug users. 
  Seal KH, Monto A, Dove L, Shen H, Vittinghoff E, Tracy D, Miller E, Lau E, Wright TL
• Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. 
  Huang H, Shiffman ML, Cheung RC, Layden TJ, Friedman S, Obar OT, Yee L, Chokkalingam AP, Schrodi SJ, Chan J, Catanese JJ, Leong DU, Ross D, Hu X, Monto A, McAllister LB, Gastroenterology
• Hepatic steatosis in HIV- hepatitis C coinfection: prevalence and significance compared to hepatitis C monoinfection. 
  Monto A, Dove LM, Bostrom A, Kakar S, Tien P, Wright TL, Hepatology
• Risks of a range of alcohol intake on hepatitis C-related fibrosis. 
  Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, Wright TL, Hepatology
• Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransferases. 
  Hui CK, Monto A, Belaye T, Lau E, Wright TL, Gut
• Implications for disease progression and treatment. 
  Monto A. Alcohol and Hepatitis C, Current Hepatitis Reports
• Recent perspectives on hepatitis C and human immunodeficiency virus coinfection. 
  Monto A, Wright TL, Hepatitis Index & Reviews
• Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. 
  Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL, Hepatology
• Hepatitis C and steatosis. 
  Monto A, Seminars in Gastrointestinal Disease
• The epidemiology and prevention of hepatocellular carcinoma. 
  Monto A, Wright TL, Seminars in Oncology
• Join now to see all